Abstract:To investigate the stability of glucagon-like peptide 1 (GLP-1) and glucagon in plasma under short- and long-term storage conditions. Pooled human plasma ( n =20), to which a dipeptidyl peptidase 4 (DPP4) inhibitor and aprotinin were added, was spiked with synthetic GLP-1 (intact, 7–36NH 2 as well as the primary metabolite, GLP-1 9–36NH 2 ) or glucagon. Peptide recoveries were measured in samples kept for 1 and 3 h at room temperature or on ice, treated with various enzyme inhibitors, after up to three thawing–refreezing cycles, and after storage at −20 and −80 °C for up to 1 year. Recoveries were unaffected by freezing cycles or if plasma was stored on ice for up to 3 h, but were impaired when samples stood at RT for more than 1 h. Recovery of intact GLP-1 increased by addition of a DPP4 inhibitor (no ice), but was not further improved by neutral endopeptidase 24.11 inhibitor or an inhibitor cocktail. GLP-1, but not glucagon, was stable for at least 1 year. Surprisingly, the recovery of glucagon was reduced by almost 50% by freezing compared with immediate analysis, regardless of storage time. Plasma handling procedures can significantly influence results of subsequent hormone analysis. Our data support addition of DPP4 inhibitor for GLP-1 measurement as well as cooling on ice of both GLP-1 and glucagon. Freeze–thaw cycles did not significantly affect stability of GLP-1 or glucagon. Long-term storage may affect glucagon levels regardless of storage temperature and results should be interpreted with caution.

Stability of Synthetic Exendin-4 in Human Plasma in Vitro

Screening and Identification of A Targeting Peptide to Nglp-1r from Phage Display Peptide Library

Bioactivity and Structure of Analogues of Exendin-4

Purification and bioactivity of exendin-4, a peptide analogue of GLP-1, expressed in Pichia pastoris

A Site-Specific PEGylated Analog of Exendin-4 with Improved Pharmacokinetics and Pharmacodynamics in Vivo

Recent Development of Exendin-4 and Its Analogs

C-terminal Site-Specific PEGylated Exendin-4 Analog: A Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Diabetic Db/db Mice.

Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity

Expression and Purification of Exendin-4 Dimer in Escherichia Coli and Its Interaction with Glp-1 Receptor in Vitro

The construction of long-acting exendin-4 analog and its hypoglycemic effect in diabetic mice

Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris.

Intramuscular injection of palmitic acid-conjugated Exendin-4 loaded multivesicular liposomes for long-acting and improving in-situ stability

Stability of glucagon-like peptide 1 and glucagon in human plasma

[Cloning, Expressing of Exendin-4 Analogue and Bioactivity Analysis in Vivo].

The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo

Thermal stability of exenatide encapsulated in stratified dissolving microneedles during storage

Preparation and Characterization of A Novel Exendin-4 Human Serum Albumin Fusion Protein Expressed in Pichia Pastoris

Exendin-4 Improves Glucose Metabolism in Insulin-Resistant Cells by Upregulating the Phosphorylative AMPK

Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist

Screening of a phage display library of exendin-4 mutants with the extracellular domain of rat GLP-1 receptor.

A New GLP-1 Analogue with Prolonged Glucose-Lowering Activity in Vivo Via Backbone-Based Modification at the N-terminus